Ireland-based pharmaceutical company Allergan, through its subsidiaries Allergan Sales and Celestial Merger Sub, has agreed to acquire US-based development-stage biopharmaceutical company Repros Therapeutics.

Celestial Merger will purchase all outstanding shares of common stock of Repros Therapeutics for $0.67 a share, under the agreement.

The transaction was announced in December and will be closed in the first quarter of 2018.

Philippines-based life science equipment and services provider Philab Holdings plans to purchase a 67% share in pharmaceutical firm Sydenham Laboratories.

Philab will roll out a precision medicine programme post acquisition, which will boost the synergies of the two companies in the healthcare sector.